| Literature DB >> 354147 |
G R Cuna, A Calciati, M R Strada, C Bumma, L Campio.
Abstract
The results of controlled clinical trial that used high doses of medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer are reported. Two treatment reigmens were used: regimen A, 500 mg daily with a total dose of 30 g; regimen B, 1,000 mg daily with a total dose of 60 g. The overall response rates were similar, with no statistically significant difference between the two treated groups. Regimen A (lower dosage group) reached a remission rate of 44%, whereas regimen B (higher dosage group) had a remission rate of 41%. The mean duration of response was 8 months with regimen A and 9 months with regimen B. The advantages of the lower dosage regimen as opposed to the higher dosage regimen of MPA in the treatment of advanced breast cancer are discussed.Entities:
Keywords: Breast Cancer; Cancer; Clinical Research; Comparative Studies; Contraception; Contraceptive Agents, Female--administraction and dosage; Contraceptive Agents, Female--side effects; Contraceptive Agents, Progestin--administraction and dosage; Contraceptive Agents, Progestin--side effects; Contraceptive Agents--administraction and dosage; Contraceptive Agents--side effects; Developed Countries; Diseases; Europe; Family Planning; Italy; Mediterranean Countries; Medroxyprogesterone Acetate--administraction and dosage; Medroxyprogesterone Acetate--side effects; Neoplasms; Research Methodology; Southern Europe; Studies; Treatment
Mesh：
Substances：
Year: 1978 PMID： 354147 DOI： 10.1177/030089167806400204
Source DB: PubMed Journal: Tumori ISSN： 0300-8916